首页> 外文学位 >Cell-mediated immune response to porcine reproductive and respiratory syndrome virus.
【24h】

Cell-mediated immune response to porcine reproductive and respiratory syndrome virus.

机译:细胞对猪繁殖与呼吸综合征病毒的免疫应答。

获取原文
获取原文并翻译 | 示例

摘要

The cell-mediated immune (CMI) response of pigs to porcine reproductive and respiratory syndrome virus (PRRSV) is low in magnitude and appears late after infection. The ability of PRRSV to suppress CMI response is not known. We reported in this dissertation that PRRSV has the ability to significantly suppress CD25, interferon gamma (IFNgamma), and tumor-necrosis factor alpha expression by T cells in response to concanavalin A and phorbol 12-myristate 13-acetate plus ionomycin, respectively. The suppressive ability of PRRSV associated with PRRSV virulence and type of myeloid antigen-presenting cells the virus infect. Virulent PRRSV significantly suppressed T cell response, whereas attenuated PRRSV did not. Monocytes supported T cell suppression more effectively than monocyte-derived macrophages and immature monocyte-derived dendritic cells. T cell suppression negatively associated with increased interleukin-10 (IL-10) gene expression. Neutralization of IL-10 activity by anti-swine IL-10 monoclonal antibodies inhibited T cell suppression.; PRRSV modified-live Virus (MLV) vaccine is currently used in the field to control diseases caused by PRRSV. To enhance CMI response to PRRSV MLV vaccine, five different vaccine adjuvants (bacterial endotoxin-derived adjuvant, mixed open reading frame 5 (ORF5) peptides derived from 5 PRRSV isolates, porcine IFNalpha, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose, and porcine IL-12) were studied. Administration of mixed ORF5 peptides at 14 and 28 days after PRRS MLV vaccination significantly increased IFNgamma production in CD4-CD8+gammadelta +, CD4-CD8-gammadelta+, and CD4-CD8+gammadelta- T cells. Administration of porcine IL-12 at 1 day after PRRS MLV vaccination significantly increased IFNgamma production in CD4+CD8 +gammadelta-, CD4-CD8+gammadelta +, and CD4-CD8+gammadelta - T cells. Significantly increased IFNgamma expression in CD4 +CD8+gammadelta-, CD4-CD8 +gammadelta+, CD4-CD8+gammadelta - T cells but not CD4-CD8-gammadelta + T cells were correlated significantly with the reduction of lung lesion scores and viremia after virulent PRRSV challenge. Administration of porcine IFNalpha at -1, 0, and 1 day and porcine IL,-12 at 1 day after PRRS MLV vaccination significantly increased CD25 expression in CD4-CD8 +gammadelta+ T cells. However, the increased CD25 expression did not correlate with protection. None of the vaccine adjuvants contributed to the reduction of lung lesion scores and viremia in comparison to PRRS MLV alone.
机译:猪对猪繁殖与呼吸综合症病毒(PRRSV)的细胞介导的免疫(CMI)反应强度低,在感染后出现。 PRRSV抑制CMI响应的能力尚不清楚。我们在这篇论文中报告说,PRRSV具有分别抑制伴刀豆球蛋白A和佛波醇12-肉豆蔻酸酯13-乙酸盐加上离子霉素的T细胞对CD25,干扰素γ(IFNγ)和肿瘤坏死因子α表达的抑制能力。 PRRSV的抑制能力与病毒感染的PRRSV毒力和髓样抗原呈递细胞的类型有关。毒性PRRSV显着抑制T细胞反应,而减毒PRRSV没有。单核细胞比单核细胞衍生的巨噬细胞和未成熟的单核细胞衍生的树突状细胞更有效地支持T细胞抑制。 T细胞抑制与白介素10(IL-10)基因表达增加负相关。抗猪IL-10单克隆抗体对IL-10活性的中和抑制了T细胞的抑制。 PRRSV修饰活病毒(MLV)疫苗目前在该领域中用于控制PRRSV引起的疾病。为了增强CMI对PRRSV MLV疫苗的反应,五种不同的疫苗佐剂(细菌内毒素佐剂,混合的开放阅读框5(ORF5)肽,衍生自5种PRRSV分离株,猪IFNα,多聚肌苷-聚胞苷酸(用聚赖氨酸和羧甲基纤维素稳定化)和猪研究了IL-12)。在PRRS MLV疫苗接种后第14天和第28天给予混合ORF5肽,可显着提高CD4-CD8 +γ+,CD4-CD8-γ+和CD4-CD8 +γ-T细胞中IFNγ的产生。在PRRS MLV疫苗接种后1天给予猪IL-12,可显着增加CD4 + CD8 +γ-,CD4-CD8 +γ+和CD4-CD8 +γ-T细胞中IFNγ的产生。 CD4 + CD8 +γδ,CD4-CD8 +γδ+,CD4-CD8 +γδ-T细胞中IFNγ的表达显着增加,而CD4-CD8-γδ+ T细胞与强毒后肺损伤评分和病毒血症的降低没有显着相关性PRRSV挑战。在PRRS MLV疫苗接种后第-1、0和1天施用猪IFNalpha,在第1天施用猪IL-12,显着增加了CD4-CD8 +γ+ T细胞中CD25的表达。但是,增加的CD25表达与保护无关。与单独使用PRRS MLV相比,没有任何疫苗佐剂有助于降低肺部病变评分和病毒血症。

著录项

  • 作者

    Charerntantanakul, Wasin.;

  • 作者单位

    Iowa State University.;

  • 授予单位 Iowa State University.;
  • 学科 Agriculture Animal Pathology.; Biology Virology.; Biology Veterinary Science.
  • 学位 Ph.D.
  • 年度 2006
  • 页码 142 p.
  • 总页数 142
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 动物医学(兽医学);动物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号